Esther Masih‐Khan
- Hematology top 1%
- Multiple Myeloma Research and Treatments 70
- Chronic Myeloid Leukemia Treatments 7
- Oncology top 5%
- Cancer Treatment and Pharmacology 27
- Peptidase Inhibition and Analysis 15
- Molecular Biology top 10%
- Protein Degradation and Inhibitors 33
- Cancer therapeutics and mechanisms 8
- Genetics top 10%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 7
-
- Cancer Mechanisms and Therapy 6
- Co-authors
- Suzanne TrudelDonna ReeceVishal KukretiGregory P. DubéChristine ChenJaime O. ClaudioA. Keith StewartYoung Trieu
- Cited by
- HematologyOncologyMolecular Biology
- Partner nations
- CanadaUnited StatesUnited Kingdom
In The Last Decade
Esther Masih‐Khan
74 papers receiving 1.3k citations
Peers
Comparison fields: 5 of 78
- Hematology 814
- Oncology 539
- Molecular Biology 886
- Genetics 116
- Cancer Research 105
Countries citing papers authored by Esther Masih‐Khan
This map shows the geographic impact of Esther Masih‐Khan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Esther Masih‐Khan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Esther Masih‐Khan more than expected).
Fields of papers citing papers by Esther Masih‐Khan
This network shows the impact of papers produced by Esther Masih‐Khan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Esther Masih‐Khan. The network helps show where Esther Masih‐Khan may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Esther Masih‐Khan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 1 | |
| 2 | 2023 | 2 | |
| 3 | 2023 | 10 | |
| 4 | 2022 | 7 | |
| 5 | 2022 | 3 | |
| 6 | 2022 | 1 | |
| 7 | 2020 | 8 | |
| 8 | 2018 | 8 | |
| 9 | 2018 | 3 | |
| 10 | 2017 | 5 | |
| 11 | 2017 | 1 | |
| 12 | 2017 | 100 | |
| 13 | 2016 | 12 | |
| 14 | 2014 | 5 | |
| 15 | 2013 | 3 | |
| 16 | 2004 | 70 | |
| 17 | 2004 | 45 | |
| 18 | 2003 | 7 | |
| 19 | 2001 | 92 | |
| 20 | 2001 | 112 |
About Esther Masih‐Khan
Esther Masih‐Khan is a scholar working on Hematology, Oncology and Genetics, having authored 79 papers that have together received 1.3k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (70 papers), Protein Degradation and Inhibitors (33 papers), Cancer Treatment and Pharmacology (27 papers), Peptidase Inhibition and Analysis (15 papers), Cancer therapeutics and mechanisms (8 papers), Chronic Myeloid Leukemia Treatments (7 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (7 papers) and Cancer Mechanisms and Therapy (6 papers). The work is most often cited by research in Hematology (814 citations), Oncology (539 citations) and Molecular Biology (886 citations). Esther Masih‐Khan has collaborated with scholars based in Canada, United States and United Kingdom. Frequent co-authors include Suzanne Trudel, Donna Reece, Vishal Kukreti, Gregory P. Dubé, Christine Chen, Jaime O. Claudio, A. Keith Stewart, Young Trieu, Rodger E. Tiedemann and Víctor H. Jiménez‐Zepeda.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.